Prof Dr Johannes Zanzinger
Investment Manager at Boehringer Ingelheim Investment Fund
Johannes has been an investment manager at the Boehringer Ingelheim (BI) Venture Fund (BIVF) since May 2019, and serves as a director at AgomAb Therapeutics in Gent, Eyevensys in Paris, and HepaRegeniX in Tübingen; he is also Adjunct Professor of Physiology at the University of Ulm in Germany. Johannes gained research and development and management experience across multiple disease states in academia, as well as in industry at Pfizer and BI. At BI, he led global business development and licensing for cardiometabolic diseases from 2007 to 2019, resulting in a series of preclinical and clinical partnering transactions contributing to BI’s current pipeline and product portfolio. Johannes was trained in animal sciences and biology at the University of Hohenheim in Germany, and held academic positions at the Medical Faculties of the Universities of Freiburg and Heidelberg until 1998.